Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of December
2019
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Seroquel rights
agreement complete: Europe, Russia
16 December 2019 07:00 GMT
Agreement with Cheplapharm for rights
to Seroquel
and Seroquel XR in Europe and Russia
completed
AstraZeneca has completed an agreement to divest its commercial
rights to Seroquel (quetiapine fumarate immediate release)
and Seroquel XR (quetiapine fumarate extended release) in
Europe and Russia to Cheplapharm Arzneimittel GmbH
(Cheplapharm).
Financial considerations
Under the terms of the
agreement, AstraZeneca has received a payment of $178m from
Cheplapharm. The Company may also receive future sales-contingent
payments of up to $61m. The upfront payment will be reported in
AstraZeneca's financial statements within Other Operating Income
& Expense in the fourth quarter of 2019.
Pursuant to Listing Rule 10.4.1R (notification of class 2
transactions), the gross book value of assets subject to the
divestment as at 31 December 2018 was nil. In the year to 31
December 2018, the aggregate profit before tax attributable
to Seroquel and Seroquel XR in the relevant territories was $86m. The
consideration was paid in cash and the proceeds will be used for
general corporate purposes.
About Seroquel
Seroquel and Seroquel XR are atypical anti-psychotic medicines with
antidepressant properties. The main indications
for Seroquel are the treatment of schizophrenia and
bipolar disorder. Seroquel XR is also approved in some markets for major
depressive disorder and generalised anxiety
disorder.
AstraZeneca previously divested the rights
to Seroquel and Seroquel XR in the UK, Japan and other major
international markets. AstraZeneca also agreed to divest the rights
to the medicines in the US and Canada to Cheplapharm earlier in
2019.
About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Media
Relations
|
|
|
Gonzalo
Viña
|
|
+44 203
749 5916
|
Rob
Skelding
|
Oncology
|
+44 203
749 5821
|
Rebecca
Einhorn
|
Oncology
|
+1 301
518 4122
|
Matt
Kent
|
BioPharmaceuticals
|
+44 203
749 5906
|
Jennifer
Hursit
|
Other
|
+44
203 749 5762
|
Christina Malmberg
Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
Investor
Relations
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
Christer
Gruvris
|
BioPharmaceuticals
(Cardiovascular, Metabolism)
|
+44 203
749 5711
|
Nick
Stone
|
BioPharmaceuticals
(Renal) Environmental, Social and Governance
|
+44 203
749 5716
|
Josie
Afolabi
|
BioPharmaceuticals
(Respiratory)
Other
medicines
|
+44 203
749 5631
|
Craig
Marks
|
Finance
Fixed
income
|
+44
7881 615 764
|
Jennifer
Kretzmann
|
Corporate
access
Retail
investors
|
+44 203
749 5824
|
US
toll-free
|
|
+1 866
381 72 77
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
16 December
2019
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|